X
Total 422235 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Excitatory post synaptic potential | A temporary change in postsynaptic membrane potential, usually a depolarization, resulting from presynaptic release of neurotransmitter. This is usually due to the flow of positively charged ions into the postsynaptic cell, but can also be due to a reduction in negatively charged ionic current or the turning off of a potassium current. An EPSP generally increases the likelihood of action potential discharge in the postsynaptic neuron. In common usage, the EPSP typically refers to an evoked EPSP. | ILX:0104006 | 6 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Excitatory postsynaptic current | Any synaptic current which increases the likelihood of an action potential firing. Typically this is mediated by an increase in sodium or calcium conductance or a decrease in potassium conductance. It is usually synonymous with an evoked excitatory post synaptic current., Any synaptic current which increases the likelihood of an action potential firing. Typically this is mediated by an increase in sodium or calcium conductance or a decrease in potassium conductance. It is usually synonymous with an evoked excitatory post synaptic current., Any synaptic current which increases the likelihood of an action potential firing. Typically this is mediated by an increase in sodium or calcium conductance or a decrease in potassium conductance. It is usually synonymous with an evoked excitatory post synaptic current. | ILX:0104007 | 7 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Excitotoxicity | ILX:0104008 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Excitotoxin | Compounds that act to damage or kill nerve cells through the process of excitotoxicity. Excitotoxicity occurs when receptors for the excitatory neurotransmitter glutamate such as the NMDA receptor and AMPA receptor are overactivated. Excitotoxins like NMDA and kainic acid which bind to these receptors, as well as pathologically high levels of glutamate, can cause excitotoxicity by allowing high levels of calcium ions[1] (Ca2+) to enter the cell. Ca2+ influx into cells activates a number of enzymes, including phospholipases, endonucleases, and proteases such as calpain. These enzymes go on to damage cell structures such as components of the cytoskeleton, membrane, and DNA. (Adapted from Wikipedia) | ILX:0104009 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Excrescence | ILX:0104010 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Execution Status | Execution status of print job. | ILX:0104011 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Execution Status Info | Additional information about Execution Status (2100,0020). | ILX:0104012 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Executive function | A top-down system that manages and controls other cognitive processes, allowing goal-directed behavior. | ILX:0104013 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Exemestane | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation. Pharmacology: Aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (Arimidex ), letrozole (Femara ) and exemestane (Aromasin ). Mechanism of action: Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Aromatase Inhibitors | ILX:0104014 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Exenatide | Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally occuring peptide. Pharmacology: Exenatide is an incretin mimetic, which has glucoregulatory effects. While it is has blood-sugar lowering actions alone, it can also be combined with other medications such as pioglitazone, metformin, sulfonylureas, and/or insulin to improve glucose control. The approved use of exenatide is with either sulfonylureas, metformin and thiazolinediones. The medication is injected twice per day using a pre-filled pen device. Typical human responses to exenatide plus eating include improvements in the initial rapid release of endogenous insulin, suppression of glucagon release by the pancreas, regulation of gastric empyting and reduced appetite; all behaviors more typical of individuals without blood sugar control problems. Exenatide is self-regulating in that in lowers blood sugar when levels are elevated but does not continue to lower blood sugar when levels return to normal, unlike with sulfonylureas or insulins. Mechanism of action: Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meals. Drug type: Approved. Biotech. Investigational. Drug category: | ILX:0104015 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Expected Completion Date and Time | Date on which the Procedure Step is expected to be completed. | ILX:0104016 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Experiment | A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena. The experiment is a cornerstone in empirical approach to knowledge. (adapted from wikipedia.org) | ILX:0104017 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Experimental autoimmune encephalomyelitis | Encephalomyelitis induced by inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin. The innoculation triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5)(adapted from Experimental Factor Ontology EFO_0001066) | ILX:0104018 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Experimental paradigm | ILX:0104019 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Experimental protocol | A resource that provides detailed plans for a scientific experiment, medical trial, or other piece of research. | ILX:0104020 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Experimental psychology | Experimental psychologists regard psychology as a natural science; research is conducted with the help of experimental methods. The concern of experimental psychology is discovering the processes underlying behavior and cognition.Experimental psychology is a methodological approach rather than a subject and encompasses varied fields within psychology. Experimental psychologists have traditionally conducted research, published articles, and taught classes on neuroscience, developmental psychology, sensation, perception, attention, consciousness, learning, memory, thinking, and language. Recently, however, the experimental approach has extended to motivation, emotion, and social psychology. - definition adapted from Wikipedia | ILX:0104021 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Experimenter | ILX:0104022 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Explicit memory | the conscious, intentional recollection of previous experiences and information. | ILX:0104023 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Exposed Area | Typical dimension of the exposed area at the detector plane. If Rectangular: row dimension followed by column; if Round: diameter. Measured in cm. The exposed area should be consistent with values specified in the , if present. This may be an estimated value based on assumptions about the patient's body size and habitus. This attribute is used in the with units in mm (see , ). | ILX:0104024 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Exposure Control Mode | Type of exposure control. | ILX:0104025 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X